Clinical trials: Advanced or Metastatic Solid Tumor
Advanced or Metastatic Solid Tumors
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
The goal of this interventional study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BAT8010 for injection in patients with advanced or metastatic solid tumors, explore the maximum tolerable…
- Trial name
- NCT05848466
- Testing
- BAT8010 for Injection
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Bio-Thera Solutions
Solid Tumor Cancer, Locally Advanced
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
- Trial name
- NCT07193511
- Testing
- AVZO-103, Combination Agent
- Where
- 15 sites in United States
- Volunteers
- 355 people
- Sponsor
- Avenzo Therapeutics, Inc.
Advanced or Metastatic MTAP-deleted Solid Tumors
An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors
This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it…
- Trial name
- NCT06568614
- Testing
- BG-89894
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 29 people
- Sponsor
- BeOne Medicines
Metastatic Solid Tumors
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations.
- Trial name
- BOREALIS-1 (NCT07021898)
- Testing
- ERAS-4001, ERAS-4001 in combination
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Erasca, Inc.
Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with…
- Trial name
- NCT07407504
- Testing
- GenSci145 tablets
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Solid Tumors
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid…
- Trial name
- NCT05644626
- Testing
- BGB-B167, Tislelizumab
- Sponsor
- BeiGene
Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma
A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Recurrent or Refractory Medulloblastoma, Locally Advanced or Metastatic Basal Cell Carcinoma
- Trial name
- NCT01106508
- Testing
- LEQ506
- Where
- 5 sites in United States, Netherlands and 2 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors
Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
This is a phase 1, open-label study designed to determine the interaction of rifampin with linifanib.
- Trial name
- NCT01401933
- Testing
- Linifanib, Rifampin
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Abbott
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT04799054
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 188 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Locally Advanced or Metastatic Solid Tumor
A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects
This study will adopt a Single-center, Single-arm, Open, Fixed Sequence design to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects.
- Trial name
- NCT06619951
- Testing
- VC004 and Itraconazole, VC004 and rifampicin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Neoplasm, Lymphomas
Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas
Studies of PEG-paclitaxel have been terminated
- Conditions
- Neoplasm, Lymphomas, Neoplasm Metastasis
- Trial name
- NCT00023166
- Testing
- PEG-paclitaxel
- Sponsor
- Enzon Pharmaceuticals, Inc.
Solid Tumor
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid…
- Trial name
- NCT05907980
- Testing
- ROSE12, Atezolizumab, Pembrolizumab
- Where
- 14 sites in United States, Japan
- Volunteers
- 209 people
- Sponsor
- Chugai Pharmaceutical
Tumors, Neoplasm Metastasis
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
- Trial name
- NCT00207103
- Testing
- Brivanib, Brivanab
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- Bristol-Myers Squibb
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.
Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the…
- Trial name
- STARTRK-1 (NCT02097810)
- Testing
- Entrectinib
- Where
- 10 sites in United States, South Korea
- Volunteers
- 84 people
- Sponsor
- Hoffmann-La Roche
Positron-Emission Tomography, Metastatic Solid Tumors
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with…
- Trial name
- iCorrelate (NCT03802123)
- Testing
- ⁸⁹Zr-Df-IAB22M2C
- Where
- 15 sites in United States
- Volunteers
- 52 people
- Sponsor
- ImaginAb, Inc.
Advanced or Metastatic Solid Tumors
Phase I of XKH002 Injection in Patients
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or…
- Trial name
- NCT06196762
- Testing
- XKH002 Injection
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Advanced Malignant Solid Tumors
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs…
- Trial name
- NCT00958724
- Testing
- Neratinib, Vinorelbine
- Where
- 2 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Puma Biotechnology, Inc.
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Neoplasm Metastases
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01273480
- Testing
- Sequence 1, Sequence 2
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.